ecancer

ecancer is a charity with a mission to raise the standards of care for cancer patients across the world through education. #openaccess

[ecancer @ecancer]

ecancer presents a free live interactive webinar on the latest in #bladdercancer on 16 November 17:00 GMT/18:00 CET. Register here for expert analysis 👉https://t.co/9uWXJtDBmu #ESMO26 #EMUC2026 #EMUC26 @AlisonBirtle @nachoduranm @amerseburger @MRoupret

[ecancer @ecancer]

Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC. Watch Dr Alex Spira discuss his study 👉https://t.co/qr0fBy34fK @AlexSpiraMDPhD @VCSpecialists #NSCLC #Oncology #WCLC2026

[Ryan R. Lion, MD @RyanRLion]

Our newly published work in @ecancer! 🌍

Together with @assoGFAOP, we implemented a structured health-system assessment/improvement framework across pediatric oncology centers in Francophone Africa, identifying priorities & building a path to action.🎗️

https://t.co/PVz9CcxZjZ

[Olaleke Folaranmi @DrGeeONE]

Hot off the press!

Quality indicators of pathology and laboratory medicine in cancer: a narrative synthesis of published literature - ecancer
#ecancer @ecancer
https://t.co/kQJyne82Gv

[ecancer @ecancer]

Join the free ecancer live interactive webinar on telepathology in breast cancer care in LMICs 12:00 BST / 11:00 UTC 25th September. Part of the Grand Rounds in Breast Cancer series. Register👉 https://t.co/jHAt5hkwRD #BreastCancer #oncology

[Dra. María Natalia Gandur Quiroga @nataliagandur]

🚀 Opening #IUCS26 | More than a meeting a growing global GU oncology community

One of the things that struck me most from the opening session was the clarity of the vision behind IUCS: to build a truly international, multidisciplinary community around better care for patients with GU cancers.

With the creation of IUCS CIC, that vision now has a formal non-profit structure focused on:

⚪ multidisciplinary care
⚪ translational and investigator-led research
⚪ evidence-based innovation
⚪ education and global collaboration
⚪ connecting science with everyday clinical practice

What makes this especially meaningful is the diversity of perspectives brought together across countries, specialties and healthcare systems — all around one shared goal:

better outcomes for our patients.

A great way to begin two days of science, discussion and collaboration in Guildford.

With leadership and contributions from @gbanna74 @ravikanesvaran @PasRescigno @alison_tree @amg120395 @ManiamAkash @neerajaiims @montypal @PGrivasMDPhD @ParamMariappan @DrYukselUrun @dmukherji @MicheleMaffezz @yekeduz_emre and the wider #IUCS26 faculty.

@myESMO @ASCO @ASCOPost @AmerUrological @urotoday @UrologyTimes @OncLive @ecancer @Uroweb

#GUOncology #UroOnc #ClinicalResearch #MedicalEducation #GlobalOncology

[ecancer @ecancer]

At #EHA2026, Dr Fredrick Chen discusses UK ITP Registry data showing rapid and robust platelet responses with early romiplostim in acute ITP. Watch the full interview👉https://t.co/FKbyOzoUO6 #ITP #Haematology

[ecancer @ecancer]

At #ESMOGI26, Dr Kozo Kataoka (@HyomedGastro) discusses GALAXY data showing postoperative ctDNA can identify colorectal liver metastasis patients most likely to benefit from adjuvant chemotherapy. Watch the interview👉 https://t.co/Uhtu4KHgK0
#CRC #ctDNA #MRD #PrecisionMedicine

[ecancer @ecancer]

At #ESMOGI26, @CentralParkWMD discusses GLEAM results. Zolbetuximab plus gemcitabine and nab-paclitaxel did not improve survival in CLDN18.2-positive MPC, highlighting the need for better patient selection and combination strategies. Watch the video👉https://t.co/LLCob9g8Bp

[ecancer @ecancer]

At #ESMOGI26, @TaberneroJosep discusses that adagrasib plus cetuximab achieved higher response rates, including more CRs, in previously treated KRAS G12C-mutated mCRC, but did not significantly improve PFS or OS vs chemotherapy. Watch the interview👉https://t.co/KFhJ9y5GFe

[ecancer @ecancer]

At #ESMOGI26, Dr Michele Milella (@UniVerona) discusses targeted intratumoural phosphorus-32 microparticles plus FOLFIRINOX in uLAPC, showing encouraging local disease control and supporting further study of this combined approach. Watch the interview👉https://t.co/57ogiSpOnP

[ecancer @ecancer]

At #ESMOGI26, Dr Nilo Azad (@hopkinskimmel) discusses early phase 1 results of dual RAS inhibition with zoldonrasib plus daraxonrasib in heavily pretreated KRAS G12D-mutated metastatic pancreatic cancer, showing encouraging activity. Watch interview👉https://t.co/RJiXjh93Nf

[ecancer @ecancer]

At #EHA2026, Prof Martin Schrappe (@UKSH_KI_HL) discusses that blinatumomab improved 4-year EFS to 83% vs 70% with intensive chemotherapy in high-risk paediatric B-ALL, while reducing relapse and severe treatment-related toxicities. Watch the interview👉https://t.co/AKbiQPSjso

[ecancer @ecancer]

At #EHA2026, @MarekTrnenyDr discusses phase 2 CHEPA results showing brentuximab vedotin plus CHP and etoposide achieved a 91% ORR and 76% complete metabolic response rate in previously untreated CD30+ PTCL. Watch the interview👉https://t.co/meOz4d6YMg #Lymphoma #Haematology

[ecancer @ecancer]

At #EHA2026, Prof Umberto Vitolo (@fprc_candiolo) discusses phase 3 frontMIND results showing tafasitamab plus lenalidomide and R-CHOP reduced the risk of progression or death by 25% in previously untreated high-risk DLBCL. Watch interview👉https://t.co/VxIUlKppCn #Haematology

[ecancer @ecancer]

Join the free ecancer live interactive webinar on telepathology in breast cancer care in LMICs 12:00 BST / 11:00 UTC 25th September. Part of the Grand Rounds in Breast Cancer series. Register👉 https://t.co/jHAt5hkwRD #BreastCancer #oncology

[ecancer @ecancer]

At #EHA2026, Prof Umberto Vitolo (@fprc_candiolo) discusses updated EPCORE DLBCL-3 results showing fixed-duration epcoritamab achieved a 73% ORR and 63% CR rate in frail, elderly patients with newly diagnosed DLBCL. Watch his interview👉https://t.co/O7yGtnUU8U #DLBCL #Haematology

[ecancer @ecancer]

At #EHA2026, Prof Anthony Moorman (@UniofNewcastle) discusses UKBlinPredict, using early MRD response and genetic markers such as IKZF1plus and DUX4 rearrangements to predict relapse risk after blinatumomab in B-ALL. Watch the interview 👉 https://t.co/fWjhtYXOZu #ALL

[ecancer @ecancer]

At #EHA2026, @carsten_niemann discusses prospective validation of CLL-TIM, a machine-learning model predicting severe infection or treatment need within 2 years in newly diagnosed, asymptomatic CLL. Watch the full interview👉https://t.co/EvqoSwKy7w #CLL #Haematology

[ecancer @ecancer]

At #EHA2026, @chanyooncheah discusses phase 3 SOUNDTRACK F1 results showing surovatamig plus rituximab achieved response rates of 95–100% and CR rates of around 84–85% in previously untreated FL. Watch full interview👉 https://t.co/UWPykwever
#FollicularLymphoma #Haematology